Coherus Oncology Inc
CHRS
NASDAQ
Biotechnology
$1.20
USD
+0.06 (+5.26%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $176.13M
Volume 635.9K
Revenue
$50.94M
TTM
+61.0%
YoY
Gross Margin
69%
TTM
+8.5%
YoY
Net Income
$-132.13M
TTM
-173.5%
YoY
Operating Cash Flow
$-186.03M
TTM
-75.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 10.3 | 11.6 | 12.7 | 12.3 | 14.3 |
YoY Growth | -0.4% | +91.2% | +64.9% | +62.0% | +39.5% |
Cost of Revenue | 3.4 | 3.7 | 4.0 | 3.8 | 4.2 |
Gross Profit | 6.9 | 7.9 | 8.7 | 8.5 | 10.1 |
Selling, General & Administrative | 26.0 | 24.9 | 23.6 | 23.1 | 21.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 52.3 | 52.2 | 54.6 | 44.6 | 42.4 |
Operating Income | -45.5 | -44.3 | -45.9 | -36.2 | -32.3 |
EBITDA | -44.5 | -43.4 | -45.0 | -35.3 | -31.5 |
Other Income / Expense | 2.9 | 2.1 | 1.8 | 1.4 | 1.3 |
Total Other Income / Expense | 0.6 | -0.2 | -0.5 | -0.8 | -1.0 |
Income Before Income Taxes | -44.9 | -44.5 | -46.3 | -36.9 | -33.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | 297.8 | -35.5 | -37.6 | -38.3 | -20.6 |
Consolidated Net Income / Loss | 297.8 | -35.5 | -37.6 | -38.3 | -20.6 |
Net Income Attributable to Common Shareholders | 297.8 | -35.5 | -37.6 | -38.3 | -20.6 |
Basic EPS | $2.57 | -$0.31 | -$0.31 | -$0.28 | -$0.13 |
Diluted EPS | $2.57 | -$0.31 | -$0.31 | -$0.28 | -$0.13 |
Basic Shares Outstanding | 116.1M | 116.2M | 120.4M | 136.4M | 154.8M |
Diluted Shares Outstanding | 116.1M | 116.2M | 120.4M | 136.4M | 154.8M |